Core Viewpoint - Pasithea Therapeutics is presenting its lead program, Basel IV, which is the first macrocyclic MEK inhibitor to enter clinical trials, highlighting its differentiated profile in terms of safety, pharmacokinetics, and early signs of efficacy [3]. Company Overview - Pasithea Therapeutics is participating in Oppenheimer's 36th Annual Life Sciences Conference, showcasing its innovative approach in the biotech sector [1]. - The CEO of Pasithea, Tiago Reis Marques, emphasizes the company's commitment to advancing its clinical programs despite personal health challenges [2]. Product Focus - The lead program, Basel IV, targets neurofibromas associated with neurofibromatosis type 1, specifically focusing on plexiform neurofibromas and cutaneous neurofibromas [3]. - The presentation will include data supporting the safety and pharmacokinetic profile of Basel IV, as well as early efficacy results in monotherapy [3].